Royalty Report: Drugs, obesity, Diabetes Treatment – Collection: 362529

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • obesity
  • Diabetes Treatment
  • Diagnostic
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 362529

License Grant
Licensor hereby grants to Licensee a non-exclusive license in the Territory to practice under the Patent Rights to make, have made, use, import, sell and offer to sell Products in the Field. This license shall be non-transferable and non-sublicensable, except that Licensee is entitled to grant sublicenses to practice under the Patent Rights (i) to its Affiliates, and (ii) to third parties, but solely to the extent necessary to enable such Affiliates and third parties to make, have made, use, import, sell and offer to sell Products in the Field together with Licensee or on Licensee’s behalf (entities in (i) and (ii) referred to as Sublicensees). Sublicensees include, as an example, third parties or Affiliates that license intellectual property rights to Products from Licensee in addition to any sublicense under the Patents.

If the making, having made, use, offer for sale, sale or import by Licensee or its Sublicensees of Axokine® or an Axokine derivative for treating obesity or obesity related disorder would infringe during the term of this Agreement a method or use claim which Licensor (or any of its Affiliates) owns on the Effective Date and which claim is not covered by the grant, Licensor hereby grants to Licensee to the extent Licensor (or its Affiliate) is legally able to do so, a non-exclusive license in the Territory under such claim solely for Licensee and its Sublicensees to develop, make, have made, use, sell, offer to sell or import Axokine or Axokine derivatives for such disorders, and in such case, such claim shall be treated as part of the Patent Rights licensed under this Agreement for all purposes, including royalty obligations. Licensor agrees that neither it nor any of its Affiliates shall take any action that would restrict Licensor’s ability to grant Licensee the non-exclusive license referred to in this agreement.

License Property
Patent Rights means
6,565,869 – Use of CNTF (ciliary neurotrophic factor) receptor activators for the treatment of obesity

Axokine is a polypeptide having the structure of human ciliary neurotrophic factor with Ala at position 17 Arg at position 63 and a fifteen amino acid deletion at the carboxy-terminus.
An Axokine derivative is a CNTF polypeptide molecule having deletions, substitutions and/or additions in its amino acid sequence.

Product means any preparation for sale by prescription, over-the-counter, or any other method, containing one or more compounds that act on the ciliary neurotrophic factor
(CNTF) receptor. For the purposes of this Agreement, a compound binding to the CNTF receptor shall be deemed to act at the CNTF receptor. Reference to compound in this definition, includes, without limitation, polypeptide based products.

Field of Use
Field of use is for the treatment of obesity. Field means all uses of Products.

IPSCIO Record ID: 211867

License Grant
The English Licensor, the technology transfer company of College, grants to the Licensee
– a worldwide, exclusive license, with the right to grant sublicenses, under the Licensed Patents, from an English University, to do all acts which would otherwise infringe the Licensed Patents including, without limitation, the right to Exploit the Licensed Products and Diagnostic Products and provide Licensed Services or otherwise do all acts which would otherwise infringe a Valid Claim of the Licensed Patents; and
– a worldwide, exclusive license, with the right to grant sublicenses in connection with a grant of sublicenses of the Licensed Patents, to use the Biological Materials in the Field, including, without limitation, the right to Exploit the Licensed Products and Diagnostic Products and provide Licensed
Services; and
– a worldwide, non-exclusive license, with the right to grant sublicenses in connection with a grant of sublicenses of the Licensed Patents, to use the Related Technology in the Field, including, without limitation, the right to Exploit the Licensed Products and Diagnostic Products and provide Licensed Services.

Licensor grants a first right to be granted a worldwide, exclusive license to commercialize any Severable Improvements in the Field to the Licensed Patents made by Imperial and notified to Licensee, where such Severable Improvements are unencumbered by any rights of any Third Party.

License Property
The licensed patents are for Screening for Modulators of Fat Storage.

The Licensed Product is any preparation for the treatment or prevention of obesity, anorexia or diabetes in humans that incorporates either in its entirety or in shortened form the RIP140 gene or RIP140 gene product howsoever modified including without limitation nucleotides, oligonucleotides, nucleic acid vectors, peptides, polypeptides, proteins etc.;  or is an agent that binds to the RIP140 gene or an RIP140 gene product (excluding the RIP140 protein or any subunit thereof) with the purpose of enhancing, interfering with, silencing, suppressing or modulating the expression thereof such agents including without limitation complementary sequences, ligands, cDNA, mRNA, tRNA, antibodies, antibody fragments, peptides, fusion proteins, mimetics, aptamers, antisense (or other nucleic acid based gene or gene product modulators), ribozymes, molecular imprinted polymers, RNAi, microRNA, dsRNA, siRNA, shRNA, vaccines, immunotherapeutics and gene therapy products; or is an agent (including without limitation small molecule entities) that has a mechanism of action through interaction with or binding to the RIP140 protein (or a subunit thereof); and which have been identified by Licensee, Affiliate or Sublicensee as a direct result of the use of the Materials (or the use of an Improvement to the Materials licensed to Licensee or an activity that falls within a Valid Claim.

The Diagnostic Product is any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction or management of obesity, anorexia or diabetes in humans which contains or comprises either in its entirety or in shortened form the RIP140 gene or RIP140 gene product howsoever modified including without limitation nucleotides, oligonucleotides, nucleic acid vectors, peptides, polypeptides, proteins etc.; or an agent that binds to the RIP140 gene or an RIP140 gene product (excluding the RIP140 protein or any subunit thereof) with the purpose of enhancing, interfering with, silencing, suppressing or modulating the expression thereof such agents including without limitation complementary sequences, ligands, cDNA, mRNA, tRNA, antibodies, antibody fragments, peptides, fusion proteins, mimetics, aptamers, antisense (or other nucleic acid based gene or gene product modulators), ribozymes, molecular imprinted polymers, RNAi, microRNA, dsRNA, siRNA, shRNA, vaccines, immunotherapeutics and gene therapy products; or an agent (including without limitation small molecule entities) that has a mechanism of action through interaction with or binding to the RIP140 protein (or a subunit thereof); and which have been identified by Licensee, Affiliate or Sublicensee as a direct result of the use of the Materials (or the use of an Improvement to the Materials licensed to Licensee or an activity that falls within a Valid Claim.

RIP140 means nuclear receptor interacting protein 140 also known as Nrip1 (nuclear receptor interacting protein 1); and /or a target protein for nuclear receptor interacting protein 140; and/or a complex of nuclear receptor interacting protein 140 and its target protein(s).

Field of Use
The field means the in vitro or in vivo screening of compounds, molecules or compositions of matter acting against or as agonists or antagonists of RIP140 to select compounds, molecules or compositions of matter which may be useful in the treatment or prevention of obesity, anorexia or diabetes.

IPSCIO Record ID: 230807

License Grant
For the License Grants of Patent Rights and Biological Materials, the University/Medical School grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field and to develop and perform Licensed Services in the Field.

For the Related Technology, Medical School grants to Company and its Affiliates a non-exclusive, license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field and to develop and perform Licensed Services in the Field.

License Property
Patents include Method of Introducing SI RNA into adipocytes, Genes Expressed in Type II diabetes and Uses Thereof, and, Receptor-Activated Reporter Systems.  Related  Technology  means  know-how,  technical  information, research and development  information,  test results, and data necessary for the
effective  exercise of the Patent  Rights which are owned by the Medical  School.

Licensed Product means any Covered Product or Developed Product.

Covered Product means any product that cannot be manufactured, used, or sold without infringing one or more claims under the Patent Rights, incorporates some portion of one or more Biological Materials proprietary to Medical School, or  cannot be manufactured, used, or sold without using some portion of the Related Technology.

Developed Product means any product that is not a Covered Product and is developed using methods claimed in the Patent Rights or using some material portion of the Related Technology.

Licensed Service means any service that cannot be developed or performed without using at least one process that infringes one or more claims under the Patent Rights,  uses some portion of one or more Biological Materials, or  uses some portion of the Related Technology.

Field of Use
Field means drug discovery in type 2 diabetes and/or obesity with therapeutic, prophylactic, or diagnostic applications and products for treatment, prevention or diagnosis of type 2 diabetes and/or obesity.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.